In recent clinical trials, FGF21 was proven to be an independent predictor of coronary heart disease in patients with T2DM and increased cardiovascular risks and was used as a novel biomarker to predict major adverse cardiovascular events (MACEs) in patients with STEMI after PCI (49–51). This evidence concerns the gene FGF21 and coronary artery disorder.